Eli Lilly's Zepbound showed promise to treat obstructive sleep apnea in two late-stage trials. It's yet another reason to stay invested in the drugmaker. Read this story
Eli Lilly's Zepbound showed promise to treat obstructive sleep apnea in two late-stage trials. It's yet another reason to stay invested in the drugmaker. Read this story
More from CNBC | Diabetes Obesity Pharmaceuticals Health care industry S&P 500 Index Novo Nordisk A S Eli Lilly and Co Breaking News: Markets Investment strategy Markets Jim Cramer stock takes business news cnbc InvestingClub Articles Investing CNBC Investing Club: Newsletter CNBC Investing Club Health & Science Drugs CNBC Investing Club: Analysis source:tagname:CNBC US Source